Gefitinib-Sensitizing Mutations in Esophageal Carcinoma

Authors:

Abstract
The sensitivity of lung cancer to gefitinib has been found to be associated with mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR),1-3 yet similar observations are not available for other solid tumors.4 We investigated whether gefitinib-sensitizing mutations in the EGFR gene were present in human esophageal tumors.